Endocrine Abstracts

Background: Relacorilant is a highly selective glucocorticoid receptor (GR) modulator in development for the treatment of endogenous Cushing syndrome (CS). Unlike the GR antagonist mifepristone, relacorilant lacks affinity for the progesterone and other receptors. In a phase 2 study in patients with CS (Pivonello et al, 2021), relacorilant provided clinically meaningful changes in several cortisol-excess-related comorbidities, including hypertension and hyperglycemia,...